KYNMOBI Drug Patent Profile

Which patents cover Kynmobi, and when can generic versions of Kynmobi launch?

Kynmobi is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are twelve patents protecting this drug.

This drug has two hundred and fifty-nine patent family members in twenty-seven countries.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kynmobi

A generic version of KYNMOBI was approved as apomorphine hydrochloride by TP ANDA HOLDINGS on February 23^rd, 2022.

Summary for KYNMOBI

International Patents:	259
US Patents:	12
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KYNMOBI

US Patents and Regulatory Information for KYNMOBI

KYNMOBI is protected by twelve US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-004	May 21, 2020		DISCN	Yes	No	9,326,981
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-003	May 21, 2020		DISCN	Yes	No	9,283,219		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020		DISCN	Yes	No	11,419,769		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020		DISCN	Yes	No	9,044,475		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-004	May 21, 2020		DISCN	Yes	No	8,846,074		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020		DISCN	Yes	No	9,326,981
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020		DISCN	Yes	No	10,420,763		Y

International Patents for KYNMOBI

When does loss-of-exclusivity occur for KYNMOBI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KYNMOBI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010259971	Sublingual apomorphine
Australia	2017200329	SUBLINGUAL APOMORPHINE
Australia	2019200308	SUBLINGUAL APOMORPHINE
Australia	2021201259	SUBLINGUAL APOMORPHINE
Brazil	112012000204	composição farmacêutica em forma de dosagem unitária que compreende apomorfina e seu uso
Canada	2765291	APOMORPHINE SUBLINGUALE (SUBLINGUAL APOMORPHINE)
China	102480958	Sublingual apomorphine

Last updated: July 16, 2026

KYNMOBI (apomorphine hydrochloride) investment scenario and fundamentals analysis: revenue exposure, exclusivity, and generic risk

KYNMOBI (apomorphine hydrochloride) is a brand asset tied to the on-demand treatment of “off” episodes in Parkinson’s disease (PD), with commercialization shaped by (1) remaining patent and regulatory exclusivity, (2) the Orange Book listing coverage for apomorphine products, (3) settlement or litigation that can accelerate generic entry, and (4) payer and channel execution. An investment thesis depends on whether the company’s remaining IP and regulatory leverage can sustain pricing power and prescription retention against potential generic/apomorphine competitors, including pharmacy substitutes and alternate apomorphine delivery formats.

Investment view depends on the answers to one operational question: what portion of the asset’s near-to-mid-term cash flows is insulated by enforceable, product-specific IP and exclusivity, versus exposed to generic “at-risk” entry and price resets.

---

What is KYNMOBI, what is it approved for, and how does it fit in the Parkinson’s “off” episode market?

Quick read (label intent): KYNMOBI contains apomorphine hydrochloride and is used for acute, on-demand rescue treatment of “off” episodes in adults with PD who have had a clinical response to levodopa. The product is designed for rapid onset relative to other oral rescue options and targets the unmet need for fast symptom control without complex administration.

Where does KYNMOBI sit versus levodopa optimization and device-based on-demand strategies?

In PD, “off” episode treatment is split between:

• On-demand rescue: short-acting pharmacologic agents (including apomorphine formulations) intended for episodic use.
• Continuous or scheduled therapy optimization: levodopa regimens, COMT inhibitors, MAO-B inhibitors, and device-assisted strategies.
• Patient and caregiver workflow: speed of onset, administration friction, and tolerance drive adherence and switching.

Implication for investment: KYNMOBI’s commercial durability hinges on whether it remains the preferred rescue choice for patients who need fast relief and can manage the administration and adverse-effect profile. Market share can shift quickly if competing on-demand products get better payer coverage or if generic entry triggers steep price erosion.

---

What patents protect KYNMOBI and how strong is the patent estate for apomorphine “on-demand” use?

Featured snippet answer: KYNMOBI’s enforceability depends on the Orange Book–listed patents covering apomorphine hydrochloride product identity, formulation, and method-of-use, plus any secondary patents on manufacturing or delivery characteristics. In apomorphine therapy, the practical IP risk is less about general PD indications and more about product-specific chemistry/formulation claims and approved-use claims that limit generic design-around.

How to map the protection layers that typically matter for KYNMOBI

For on-demand apomorphine brands, the estate usually clusters into:

1. Drug substance identity and salt claims (apomorphine hydrochloride composition coverage)
2. Formulation claims (excipients, concentration, stabilizers, or release characteristics)
3. Method-of-use claims (treatment of PD “off” episodes, patient selection criteria)
4. Manufacturing process claims (steps, parameters, impurity control)
5. Device or administration workflow claims (when applicable to product delivery)

Patent strength scoring framework used by investors

Investors typically weight:

• Remaining term (years) on the most central claims
• Breadth of independent claims vs ability to design around
• Claim type criticality: product-specific formulation and approved method-of-use claims generally carry more enforcement leverage than broad, generic PD-use assertions.
• Litigation posture: whether patents have survived validity challenges or have settlement history.

---

When does KYNMOBI lose exclusivity and what are the effective launch windows for generics?

Featured snippet answer: the investment trigger is the earlier of:

• Patent expiration of key Orange Book–listed claims, and
• Regulatory exclusivity end dates (if applicable) tied to the original approval.

Exclusivity mechanics that drive generic timing

Even with patent protection, generic launch typically occurs only when a sponsor can file and clear:

• ANDA approval pathway (small-molecule)
• Patent certification strategy for Orange Book listings
• Paragraph IV litigation timelines and any 30-month stay effects (if triggered)

Commercial implication: cash-flow risk is concentrated in the last 2 to 3 years of the remaining protected period, when generic preparation accelerates and payer contracts often become more renegotiation-prone.

---

How many patents cover KYNMOBI on the FDA Orange Book and what claims are most at risk in a Paragraph IV challenge?

Featured snippet answer: Paragraph IV risk is highest where Orange Book listings include product-formulation and method-of-use patents with broad independent claim scope and near-expiration status. Lower risk is associated with patents that are narrow, dependent, or easily design-around.

Orange Book coverage: how investors segment the estate

A practical portfolio view separates:

• Core patents: identity/formulation/method-of-use likely to be asserted
• Secondary patents: process or narrow dependent claims with lower likelihood of blocking launch
• Residual patents: later-filed patents that may lag behind generic challenges

Paragraph IV challenge vectors for apomorphine products

Common generic strategies:

• Salt/formulation substitution while preserving intended delivery
• Different impurity profile and manufacturing process to avoid process claims
• Claim non-infringement by altering formulation parameters

---

Which companies are challenging KYNMOBI and what Paragraph IV litigation affects near-term entry risk?

Featured snippet answer: the near-term risk profile depends on whether any generic sponsor has filed an ANDA with Paragraph IV certifications against KYNMOBI’s Orange Book patents, and whether courts granted or denied preliminary injunctions or upheld validity.

What to watch in litigation records

Investor-grade signals:

• Filed ANDA with Paragraph IV
• District court claim construction outcomes
• Any stipulated settlement that sets an agreed launch date
• Appeal status and whether the case reached final judgment

Commercial implication: a settlement with a fixed “carve-out” or payment can lock in launch timing and reduce uncertainty, but it can also indicate that the brand faced non-trivial infringement/validity risks.

---

What generic entry risks exist for KYNMOBI under ANDA, and what manufacturing/IP barriers could delay launch?

Featured snippet answer: the largest generic launch barrier typically is not PD indication patent coverage; it is the ability to replicate approved product characteristics while staying out of formulation and method-of-use claims and meeting FDA CMC requirements.

Key execution risks in small-molecule ANDAs

Generic approval still requires:

• Bioequivalence to the reference listed drug (RLD)
• CMC compliance: stability, impurity limits, and process validation
• Formulation consistency that supports the intended pharmacokinetic profile

At-risk vs settled entry

Investors should separate:

• At-risk entry where a generic launches before final patent resolution, increasing probability of injunction
• Settled entry with agreed launch dates and often non-design-around-specific limitations

---

How does KYNMOBI compare with other apomorphine products and PD on-demand rescue therapies?

Featured snippet answer: KYNMOBI’s competitive position depends on differentiation versus other apomorphine formats and non-apomorphine rescue therapies in three dimensions: speed of onset, administration convenience, and payer coverage.

Competitive comparison criteria for “off” episode rescue

• Onset time and duration of effect in off episodes
• Dosing workflow for patients and caregivers
• Tolerability: nausea and orthostatic hypotension management is a key differentiator
• Form factor: ease of administration drives persistence and repeat prescriptions
• Real-world access: formulary inclusion and prior authorization constraints

Why competitive dynamics matter for investment

Even if patents remain intact, market share can erode when:

• payers steer to preferred formulary rescue options,
• competing products improve patient support programs,
• or channel inventory and rebate dynamics tilt prescribing.

---

What is the FDA regulatory status of KYNMOBI and how does FDA review affect commercialization risk?

Featured snippet answer: for a mature drug, the investment issue is less “approval pathway” and more whether post-approval commitments, label changes, or safety communications affect persistence and volume.

Regulatory factors investors track

• Safety communications that affect dosing guidance or usage restrictions
• Label expansion or narrowing that changes eligibility
• Postmarketing requirements that could trigger manufacturing changes
• Any REMS-like constraints (if applicable) that affect patient throughput

---

What commercial fundamentals drive KYNMOBI revenue, margins, and forecast accuracy?

Featured snippet answer: KYNMOBI revenue is driven by patient uptake into “off” episode rescue use, retention/persistence, and payer coverage stability. Margin is driven by net price after rebates, contract terms, and the cost of manufacturing and distribution of the on-demand formulation.

Commercial model inputs investors typically use

• Prescriptions and scripts per patient (proxy for persistence)
• Net price trajectory (rebates, discounts, commercial mix)
• Changes in formulary status and prior authorization requirements
• Competitive switching, especially after any credible generic threat windows
• Seasonality or patient-level cadence tied to PD progression stages

Revenue exposure framework

Cash-flow exposure rises sharply under scenarios where:

• patents approach expiry,
• Paragraph IV filings appear,
• settlements indicate credible design-around,
• or payers begin preemptive pricing pressure.

---

What patent litigation affects KYNMOBI licensing and settlement leverage?

Featured snippet answer: litigation posture determines whether the brand can enforce at scale or whether it shifts to settlement as a rational route to preserve market share through a predictable window.

How litigation impacts settlement economics

Settlement can:

• lock in a launch date,
• establish non-infringement carve-outs,
• define supply terms,
• or impose restrictions on generic design-around.

From an investment standpoint, the central question is whether the settlement reduces probability-weighted losses enough to justify continued R&D spending or manufacturing expansion tied to expected duration of brand exclusivity.

---

Key Takeaways

• KYNMOBI is an apomorphine-based on-demand “off episode” rescue therapy; its investment profile is driven by the ability to maintain net price and volume against generic and competitive pressures.
• The highest-value diligence is mapping the Orange Book estate by claim type and expiration timing, then tying it to the probability of Paragraph IV challenges and settlements.
• Commercial downside accelerates in the final years of remaining protection, when payer behavior and generic preparation intensify.
• Patent breadth in formulation and method-of-use typically determines whether generic entry can proceed without triggering injunction risk.

---

FAQs

1) What drug does KYNMOBI contain and what is its mechanism in PD “off” episode treatment?
KYNMOBI contains apomorphine hydrochloride and is used as on-demand rescue therapy for PD “off” episodes.

2) Does KYNMOBI’s IP risk come more from indication patents or from formulation patents?
Formulation and product-specific method-of-use patents generally drive practical launch blocking power in generic apomorphine scenarios.

3) What does an ANDA Paragraph IV filing signal for KYNMOBI investors?
It signals an intent to challenge Orange Book-listed patents and can compress the time to generic entry if courts allow or settlements set launch timing.

4) How do payer and channel dynamics affect KYNMOBI even before generic launch?
Formulary inclusion, prior authorization requirements, and rebate pressure can shift prescriptions away from the brand prior to patent expiry.

5) What milestones after approval can create commercialization risk for a mature specialty drug like KYNMOBI?
Label changes tied to safety guidance, postmarketing commitments, and manufacturing CMC requirements that affect supply and dosing usability.

---

References

1. FDA Orange Book: Approved Drug Products. (n.d.). U.S. Food and Drug Administration.
2. FDA. (n.d.). Drug Approval and Databases. U.S. Food and Drug Administration.